



05 A 08 DE NOVEMBRO DE 2025

RIO DE JANEIRO

# Excisão total do mesopâncreas: SEMPRE

**Orlando Jorge M. Torres**

Department of Gastrointestinal Surgery  
Hepatopancreatobiliary Unit  
Maranhão Federal University - Brazil



**Prof. Irene Esposito (Heidelberg – Germany)  
Pathologist - Düsseldorf, Germany**

Esposito I, et al. *Ann Surg Oncol* 2008; 15:1651–60

Encyclopedia of Pathology  
Series Editor: J.H.J.M. van Krieken

SPRINGER NATURE  
Reference [ ]

Irene Esposito  
Eva Karamitopoulou-Diamantis *Editors*

# Pathology of the Pancreas

 Springer


# Most Pancreatic Cancer Resections are R1 Resections

2008

Irene Esposito, MD,<sup>1,3</sup> Jörg Kleeff, MD,<sup>2,4</sup> Frank Bergmann, MD,<sup>1</sup> Caroline Reiser, MD,<sup>2,4</sup>  
 Esther Herpel, MD,<sup>1</sup> Helmut Friess, MD,<sup>2,4</sup> Peter Schirmacher, MD,<sup>1</sup> and  
 Markus W. Büchler, MD<sup>2</sup>

76%

## SUPERIOR MESENTERIC ARTERY




**TABLE 3.** Tumor margin characteristics of 111 consecutive macroscopic complete resections for pancreatic ductal adenocarcinoma (2005–2006)

Characteristic	Value, n (%)
R classification	
R0	27 (24%)
<b>R1</b>	<b>84 (76%)</b>
RM involvement	
Posterior	39 (47%)
<b>Medial</b>	<b>57 (68%)</b>
Anterior surface	8 (10%)
Superior	0
Transection (pancreas)	3 (4%)
Bile duct	4 (5%)
Stomach/duodenum	3 (4%)
Number of margins	
1	56 (68%)
2	22 (26%)
3 or more	5 (6%)
Type of involvement	
Direct extension	78 (93%)
Locoregional spreading	6 (7%)

**MESOPANCREAS 68%**

## Most Pancreatic Cancer Resections are R1 Resections

Irene Esposito, MD,<sup>1,3</sup> Jörg Kleeff, MD,<sup>2,4</sup> Frank Bergmann, MD,<sup>1</sup> Caroline Reiser, MD,<sup>2,4</sup>  
Esther Herpel, MD,<sup>1</sup> Helmut Friess, MD,<sup>2,4</sup> Peter Schirmacher, MD,<sup>1</sup> and  
Markus W. Büchler, MD<sup>2</sup>



R1 – Margem  $\leq$  1 mm  
Seta verde – Neoplasia  
Seta vermelha - margem

**Email para Prof. Irene Esposito  
Pathologist - Dusseldorf, Germany**

Dear Prof Esposito

Thanks a lot for your response

As a surgeon I strongly believe that the medial part of the specimen is where the smv, sma and the PLph are located and that's where we can provide a more accurate surgery in the modern concept - total mesopancreas excision

Many papers are investigating the nerves sheaths and their role in tumor dissemination.

Are you also looking into this issue?

We would love to visit you in Germany and also invite you for our meetings here in Brazil if you allow us

Your work is very much appreciated here

Warm regards

Eduardo Fernandes

Enviado do meu iPhone

**Eduardo Fernandes**

## Resposta da Prof. Irene Esposito Pathologist - Dusseldorf, Germany

Dear Dr. Fernandes,  
thank you for your email and congratulations for your publications on this topic.

The 1-mm rule should be applied to the dorsal, medial (SMV/SMA), neck and bile-duct margins.

The ventral, peritonealized surface is to be classified as R1 only when tumor cells are detected on the ink surface, so it is not affected by the 1 mm rule. You may refer to the explanatory notes of the ICCR dataset (attached) for a clarification of these topics. Please note that in some countries the presence of tumor cells within 1-mm from e.g. the medial margin is not called R1 but R0-narrow. Whatever you call it, we know that this is a prognostic unfavourable situation, which correlates with high recurrence rates.

That said, pathologists can only assess what they receive from the OR; so it is the surgeon who is required to perform an oncologic resection including the so-called "mesopancreas".

In any case, the best way for assessment is to follow a standardized protocol and to embed enough tissue for correct assessment of all margins. We advocate for the axial slicing method, which you also describe in your paper.

Have I answered your questions?

Best regards  
Irene Esposito

**1-mm rule**

Univ.-Prof. Dr. Irene Esposito



Director

Institute of Pathology

**University Hospital of Duesseldorf**  
Building 14.79  
Moorenstr. 5  
40225 Duesseldorf  
Germany

Veia mesentérica superior (SMV)  
Artéria mesentérica superior (SMA)

Mesopancreas




ORIGINAL ARTICLE

# Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study

**d - SMA margin clearance & disease free survival**

## SUPERIOR MESENTERIC ARTERY



05 A 08 DE NOVEMBRO DE 2025

RIO DE JANEIRO

ORIGINAL ARTICLE

**Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study**





05 A 08 DE NOVEMBRO DE 2025

RIO DE JANEIRO

**Conclusion:** Local recurrence of pancreatic cancer is common and associated with similar mortality rates as those who present with simultaneous or metastatic recurrence. Involvement of the SMA margin is an independent predictor for disease progression

**SUPERIOR MESENTERIC ARTERY**



**Fig. 3a** Pancreatic nerve plexuses  
(cross-sectional diagram)

**Fig. 3b** Extrapancreatic nerve plexuses

PLph I: pancreatic head nerve plexus I  
PLsma: superior mesenteric nerve plexus  
 PLhdl: hepatoduodenal ligament nerve plexus  
 PLce: celiac plexus

PLph II: pancreatic head nerve plexus II  
 PLcha: common hepatic artery nerve plexus  
 PLspa: splenic artery nerve plexus

腫瘍取扱い規約(英語版 第4版)  
 [腫瘍取扱い規約 第7版 準拠]

# Classification of Pancreatic Carcinoma



Japan Pancreas Society  
 Fourth English Edition





Kanehara & Co., Ltd.



## The mesopancreas and pancreatic head plexus: morphological, developmental, and clinical perspectives









# Common hepatic artery

# Celiac trunk


**A**




**B PLphI**




**C**




**B**



# TOTAL MESOPANCREAS EXCISION



# PLph II



**Mesopancreas**

CELIAC TRUNK

PANCREATIC HEAD AND UNCINATE


SUPERIOR MESENTERIC ARTERY




LEFT RENAL VEIN


MESENTERIC ROOT



## What do surgeons need to know about the mesopancreas

Eduardo de Souza M. Fernandes<sup>1,2</sup> · Oliver Strobel<sup>3,4</sup> · Camila Girão<sup>1,2</sup> · Jose Maria A. Moraes-Junior<sup>5,6</sup> · Orlando Jorge M. Torres<sup>5,6</sup> 







# TOTAL MESOPANCREAS EXCISION

## MESOPANCREAS

- pIph-I
- pIph-II
- IPDA
- Jejunal arteries
- Jejunal veins
- Lymph nodes



# TOTAL MESOPANCREAS EXCISION




**RATIONAL**

**1. CIRCUMFERENTIAL DISSECTION OF SMV/PV**

# TOTAL MESOPANCREAS EXCISION

□ Common hepatic artery lymph nodes 8a, 8p



**RATIONAL**



**2. HEMICIRCUMFERENTIAL DISSECTION OF CHA**

# COMMON HEPATIC ARTERY LYMPH NODES

□ 8a

□ 8p



A



## 2. HEMICIRCUMFERENTIAL DISSECTION OF CHA

# TOTAL MESOPANCREAS EXCISION

**RATIONAL**



**Superior mesenteric artery**

**Left renal vein**

**Aorta**

**3. HEMICIRCUMFERENTIAL DISSECTION OF SMA**

**IVC**

# TOTAL MESOPANCREAS EXCISION

COMMON HEPATIC ARTERY


CELIAC TRUNK

PLph I


PLph II

PLsma


SUPERIOR MESENTERIC ARTERY




# LYMPHATICS



## □ 16b1 lymph nodes







**16b1 area**

# SUPERIOR MESENTERIC ARTERY LYMPH NODES

□14p

□14d



# STATE OF THE ART

## Pancreatoduodenectomy

Total mesopancreas excision<sup>1</sup>  
“Artery first”<sup>2</sup>

Level 3 dissection<sup>3</sup>  
“Triangle operation”<sup>4</sup>

Extended resection<sup>5</sup>  
+/- portal/SM vein

Liver metastasis

1. Fernandes ES, et al. Langenbecks Arch Surg 2021


2. Inoue Y, et al. J Gastrointest Surg 2018



3. Niesen W, et al. Ann Gastroenterol Surg. 2019

4. Hackert T, et al. HPB 2017




5. Fernandes ES, et al. J Gastrointest Oncol 2023

6. Torres OJ, Zurich and Cape Town







# ARTERY FIRST



# MESENTERIC APPROACH


**ARTERY FIRST**

**INFRACOLIC APPROACH**




**MESENTERIC APPROACH**

# ARTERY FIRST





Infracolic approach

**MESENTERIC APPROACH**



# ARTERIES


# INFERIOR PANCREATODUODENAL ARTERY (IPDA)




Common trunk

THE EPICENTER OF THE PANCREATODUODENECTOMY



**Three-dimensional models of arteries constructed using multidetector-row CT images to perform pancreatoduodenectomy safely following dissection of the inferior pancreaticoduodenal artery**



**INFERIOR PANCREATODUODENAL ARTERY (IPDA)**




# INFERIOR PANCREATODUODENAL ARTERY (IPDA)



A

**IPDA**




**EPICENTRO DA DUODENOPANCREATECTOMIA**

**MESOPANCREAS**

**MESOJEJUNUM**

**IPDA**




**Dissecting line**

**FIRST JEJUNAL ARTERY**


# IPDA

(A)



(B)


Exposure of the SMA III posterior side



# MESOJEJUNUM

# FIRST JEJUNAL ARTERY

# FIRST JEJUNAL ARTERY




Inoue Y, et al. J Gastrointest Surg 2016

# MESOJEJUNUM




# TRIANGLE OPERATION



**2. HEMICIRCUMFERENTIAL DISSECTION OF CHA**


**B**




**3. HEMICIRCUMFERENTIAL DISSECTION OF SMA**

ORIGINAL ARTICLE

**The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study**



**ADVANTAGES OF ARTERY FIRST APPROACH**




**TOTAL MESOPANCREAS EXCISION**

**Portal vein resection**

**TRIANGLE OPERATION**

# TOTAL MESOPANCREAS EXCISION



Portal vein resection

**TRIANGLE OPERATION**

# Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

## A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

**ESPAC-4**

**Recurrence?**

**Table 2. Sites of First Recurrence and Median Overall Survival From Surgery and Median Survival After Diagnosis of Recurrence by Site**

Site of Recurrence	No.	Median (95% CI)		
		Recurrence-Free Survival, mo	Survival After Recurrence, mo	Overall Survival, mo
Local only	238	13.57 (12.61-14.06)	9.36 (8.08-10.48)	24.83 (22.96-27.863)
Local and distant recurrence	48	11.99 (10.28-15.83)	8.11 (5.22-11.79)	23.82 (17.48-28.32)
Distant only	193	11.14 (10.05-12.32)	9.23 (7.82-11.43)	20.61 (18.12-23.80)

**Total: 730**  
**Recurrence rate 479 (65.6%)**  
**Local 238 (479): 49.7%**  
**Distant 193 40.3%**  
**Simultaneous 48: 10.0%**


**RESIDUAL DISEASE**

## Local radicality and survival outcome of pancreatic cancer surgery

**TABLE 2** The effect of positive resection margins on survival in pancreatic cancer

Study	Type of study	Patients included	Type of surgery	R-definition	R0/R1 rate, absolute (%)	Years	Median survival	5-year survival rate	Adjuvant (chemo-) therapy			
Uesaka 2016 <sup>4</sup> JASPAC 01	RCT	385	257 (68%): PD 116 (13%): DP 4 (19%): TP	0-mm rule	R0 > 0 mm: 49 (13%) R1 0 mm: 328 (87%)	2007-2010	25.5 months	24.4%	Yes: 98.7%			
		190 GEM	136 (72%): PD 50 (26%): DP 4 (2%): TP		R0 > 0 mm: 26 (14%) R1 0 mm: 164 (86%)							
		187 S-1	121 (65%): PD 66 (35%): DP 0 (0%): TP		R0 > 0 mm: 23 (12%) R1 0 mm: 164 (88%)					46.5 months	44.1%	
Strobel 2017 <sup>41</sup>	Retrospective single-center	561	561 PD 72 (12.8%): cPD 427 (76.1%): ppPD 62 (11.1%): prPD	1-mm rule	R0 > 1 mm: 112 (20%) R1 0-1 mm: 123 (21.9%) R1 0 mm: 326 (58.1%)	2006-2012	R0 > 1 mm: 41.6 months R1 0-1 mm: 27.5 months R1 0 mm: 23.4 months	37.7%	Yes: 438 (78.1%) No: 72 (12.8%) NA: 51 (9.1%)			
		Hank 2018 <sup>42</sup>	Retrospective single-center		455		218 DP: (47.9%) 237 TP: (52.1%)	1-mm rule	R0 > 1 mm: 107 (23.5%) R1 0-1 mm: 104 (22.9%) R1 0 mm: 244 (53.6%)	R0 > 1 mm: 62.4 months R1 0-1 mm: 24.6 months R1 0 mm: 17.2 months	52.6%	Yes: 81.5% No: 18.5%
												13%



# Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer



**Local radicality**

# TRIANGLE OPERATION



Local radicality



LOCAL RECURRENCE

# TRIANGLE OPERATION



## Local radicality



# LYMPHADENECTOMY

Local radicality

## RIGHT SIDE OF SMA ?




14p, 14d



**Fig. 1.** Nodal type local recurrence of pancreatic head cancer on the left side of SMA.

**Local recurrence of pancreatic head cancer on the left side of SMA**



**Courtesy Dr. Alberto Stein (ES)**

REVIEW ARTICLE

**A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma**

James R. Butler<sup>1</sup>, Syed A. Ahmad<sup>2</sup>, Matthew H. Katz<sup>3</sup>, Jessica L. Cioffi<sup>1</sup> & Nicholas J. Zyromski<sup>1</sup>

<sup>1</sup>Indiana University School of Medicine, Department of Surgery, Indianapolis IN, <sup>2</sup>The University of Cincinnati Cancer Institute, Cincinnati OH, and <sup>3</sup>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

- R0 resection 16–79%**
- SMA most often positive (15–45%)**
- Positive margin was associated with decreased survival.**

**Conclusions:** Margin positivity in resectable pancreatic adenocarcinoma is associated with poor survival. Inability to clear the SMA margin is the most common cause of incomplete resection.



Contents lists available at ScienceDirect

International Journal of Surgery

journal homepage: [www.elsevier.com/locate/ijso](http://www.elsevier.com/locate/ijso)



Review

Superior mesenteric artery first approach can improve the clinical outcomes of pancreaticoduodenectomy: A meta-analysis




## Local radicality

- Higher R0 resection rate ( $p < 0.001$ )
- Lower local recurrence rate ( $p < 0.0001$ )
- Higher overall survival:
  - 1-year  $p=0.015$
  - 2-year  $p=0.005$
  - 3-year  $p=0.001$


Meta-analysis - 18 studies

**Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma**

**Local radicality**



**Fig. 1** Overall survival according to recurrence around the SMA. The median survival was 23.6 months in patients with recurrence around the SMA and 26 months in patients without recurrence around the SMA ( $p = 0.0367$ ) SMA: superior mesenteric artery




**Fig. 2** Overall survival according to the type of the surgery. The median survival was 40.3 months in the AFA-PD group and 22.6 months in the conventional PD group ( $p = 0.005$ ) AFA-PD: artery-first approach pancreatoduodenectomy

**40.3 months vs 22.6 months ( $p= 0.005$ )**

**OVERALL SURVIVAL**


# STATE OF THE ART

# Local radicality



## CONCLUSIONS

- ❑ Radical resection with adequate regional lymphadenectomy and radical resection around the large peri-pancreatic vessels is an important prerequisite for good oncological outcomes.
- ❑ High-quality radical surgery and modern adjuvant therapy, defined by lymph node resection and margin status, has a profound impact on survival.
- ❑ In modern pancreatic surgery, radical resections can be facilitated and achieved by several techniques, including **artery-first** approaches, a **level-3 dissection** around the arteries, the **TRIANGLE operation**, and extended resections, including **vascular resection**.



[www.drorlandotorres.com.br](http://www.drorlandotorres.com.br)



Shailesh and Thilo

Thanks!

## Lençóis Maranhenses



 [orlandotorres\\_gastrocirurgia](https://www.instagram.com/orlandotorres_gastrocirurgia)